SCHEMBL4310463

SCHEMBL4310463

COC(=O)C(C(O)c1cnccc1NC(=O)C(C)(C)C)C(C)(C)C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.39
KDM4E B2RXH2 4/20 0.36
L3MBTL1 Q9Y468 3/20 0.36
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
AAK1 Q2M2I8 1/20 0.33
CETP P11597 1/20 0.33
ALDH1A1 P00352 1/20 0.32
PDK1 Q15118 1/20 0.32
PDK2 Q15119 1/20 0.32
PDK3 Q15120 1/20 0.32
PDK4 Q16654 1/20 0.32
LMNA P02545 1/20 0.32
ALOX12 P18054 1/20 0.32
TLR9 Q9NR96 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13912949 1.00 TSHR (0.39) TSHRKDM4EL3MBTL1NPC1RAB9A
SCHEMBL9041200 0.79 TSHR (0.45) TSHRKDM4EL3MBTL1NPC1RAB9A
SCHEMBL4303760 0.77 ALDH1A1 (0.52) KDM4EL3MBTL1NPC1RAB9ASMN1; SMN2
SCHEMBL2359872 0.75 TSHR (0.34) TSHRNPC1RAB9ASMN1; SMN2AAK1
SCHEMBL9846978 0.73 TSHR (0.46) TSHRKDM4EL3MBTL1NPC1RAB9A
SCHEMBL4153508 0.72 TSHR (0.49) TSHRKDM4EL3MBTL1NPC1RAB9A
SCHEMBL5282911 0.71 BRS3 (0.42) TSHRKDM4EL3MBTL1NPC1RAB9A
SCHEMBL9209849 0.71 TSHR (0.44) TSHRKDM4EL3MBTL1NPC1RAB9A
SCHEMBL1190850 0.70 TSHR (0.49) TSHRKDM4EL3MBTL1NPC1RAB9A
SCHEMBL3899443 0.68 TSHR (0.48) TSHRKDM4EL3MBTL1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090062280-A1 Ophthalmic Compositions for Treating Ocular Hypertension MERCK SHARP & DOHME CORP. 2009-03-05 US disclosed
EP-2004193-A2 OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION Merck & Co., Inc. (US) 2008-12-24 EP disclosed
WO-2007108968-A2 OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION MERCK & CO., INC. (US) 2007-09-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090062280-A1 Ophthalmic Compositions for Treating Ocular Hypertension KCNN3, KCNN1, KCNN2 TSHR 3563/4885KDM4E 1800/4885L3MBTL1 4741/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.